Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2RA | P01589 | 1/20 | 1.00 |
| ▸ | ALB | P02768 | 1/20 | 1.00 |
| ▸ | IL2 | P60568 | 1/20 | 1.00 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.52 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.52 |
| ▸ | YAP1 | P46937 | 10/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14136732 | 1.00 | IL2RA (1.00) | IL2RAALBIL2ITGB1ITGA4 | |
| SCHEMBL6860596 | 1.00 | IL2RA (1.00) | IL2RAALBIL2ITGB1ITGA4 | |
| SCHEMBL14136720 | 1.00 | IL2RA (1.00) | IL2RAALBIL2ITGB1ITGA4 | |
| SCHEMBL15159838 | 0.92 | IL2RA (0.85) | IL2RAALBIL2ITGB1ITGA4 | |
| SCHEMBL4323694 | 0.91 | IL2RA (0.84) | IL2RAALBIL2ITGB1ITGA4 | |
| SCHEMBL4323700 | 0.91 | IL2RA (0.84) | IL2RAALBIL2ITGB1ITGA4 | |
| SCHEMBL4993522 | 0.91 | IL2RA (0.84) | IL2RAALBIL2ITGB1ITGA4 | |
| SCHEMBL4323684 | 0.91 | IL2RA (0.84) | IL2RAALBIL2ITGB1ITGA4 | |
| SCHEMBL12156024 | 0.91 | IL2RA (0.84) | IL2RAALBIL2ITGB1ITGA4 | |
| SCHEMBL15832297 | 0.91 | IL2RA (0.84) | IL2RAALBIL2ITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030149049-A1 | Small-molecule inhibitors of interleukin-2 | SUNESIS PHARMACEUTICALS, INC. | 2003-08-07 | — | — | US | claimed |
| WO-2003051797-A2 | SMALL-MOLECULE INHIBITORS OF INTERLEUKIN-2 | SUNESIS PHARMACEUTICALS, INC. (US) | 2003-06-26 | — | — | WO | claimed |
| US-6806279-B2 | FOR THERAPY OF AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS, MULTIPLE SCLEROSIS, UVEITIS, AND PSORIASIS, ALLOGRAFT REJECTION, AND GRAFT-VERSUS-HOST DISEASE | SUNESIS PHARMACEUTICALS, INC. | 2004-10-19 | — | — | US | disclosed |
| US-20030149049-A1 | Small-molecule inhibitors of interleukin-2 | SUNESIS PHARMACEUTICALS, INC. | 2003-08-07 | — | — | US | disclosed |
| WO-2003051797-A2 | SMALL-MOLECULE INHIBITORS OF INTERLEUKIN-2 | SUNESIS PHARMACEUTICALS, INC. (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149049-A1 | Small-molecule inhibitors of interleukin-2 | IL2, IL2RA, HLA-DRB1 | IL2RA 2/4885ALB 2619/4885IL2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.